Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced the closing of its initial public offering of 8,050,000 shares of its common stock at a price to the public of $26.00 per share, which includes the exercise in full by the underwriters of their option to purchase 1,050,000 additional shares of common stock for total gross proceeds of $209.3 million, before deducting underwriting discounts and commissions and other offering expenses payable by Health Catalyst. Health Catalyst’s common stock began trading on The Nasdaq Global Select Market under the symbol “HCAT” on July 25, 2019.
Goldman Sachs & Co. LLC, J.P. Morgan, and William Blair acted as joint book-running managers for the offering as representatives of the underwriters. Piper Jaffray, Evercore ISI and SVB Leerink acted as passive book-running managers for the offering. SunTrust Robinson Humphrey acted as a co-manager for the offering.
The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, tele
